Form 4: Kymera CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Kymera Therapeutics CEO Nello Mainolfi sold 30,000 shares of common stock for $49.00 per share, following an option exercise, under a pre-arranged trading plan.

Summary

• Nello Mainolfi, Chief Executive Officer and Director of Kymera Therapeutics, Inc. (KYMR), executed transactions on September 16, 2025.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 6, 2024.
• Mainolfi exercised stock options to acquire 30,000 shares of common stock at an exercise price of $2.08 per share.
• Concurrently, he sold 30,000 shares of common stock at a price of $49.00 per share.
• Following these reported transactions, Mainolfi directly owns 660,482 shares of common stock and 435,559 stock options.

Sentiment

Score: 6

Explanation: The transaction reflects a planned monetization of vested equity by the CEO under a Rule 10b5-1 plan, which is a common practice. The significant profit realized from the option exercise and sale is positive for the insider, but a CEO selling shares can sometimes be viewed with slight caution by the market, even if pre-planned.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned monetization of vested equity rather than an immediate reaction to new information.
• The sale price of $49.00 per share is significantly higher than the option exercise price of $2.08, indicating a substantial profit for the insider.

Negatives

• A sale of shares by a Chief Executive Officer, even under a 10b5-1 plan, can sometimes be interpreted by the market with slight caution, though the pre-planned nature mitigates concerns about opportunistic selling.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide specific industry context. Insider sales, even under 10b5-1 plans, are common in the biotechnology sector as executives monetize vested equity.

Stakeholder Impact

• Shareholders: May observe the CEO's share sale, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about opportunistic selling.
• Management: The CEO has monetized a portion of his equity compensation, which is a standard part of executive compensation.

Key Dates

Recommendation

The filing is a routine Form 4 detailing an insider's pre-planned sale of shares following an option exercise. While the CEO is monetizing vested equity, this transaction does not provide new fundamental information about the company's operational performance or future prospects to warrant a change in investment recommendation. The sale was executed under a 10b5-1 plan, which suggests it was not based on new, undisclosed material information. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Kymera Therapeutics, KYMR, Nello Mainolfi, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO Transaction, Biotechnology